SFDA Approves Anti-Diabetic Drug Gliclazide
SUBMITTED BY PRATIBHA MINHAS ON MON, 05/16/2011 - 09:54
China’s SFDA has approved new anti-diabetic drug Gliclazide tablets and it will be sold in the market from July this year. The drug is manufactured by Tianyin Pharmaceutical Co. Inc. the company is specialized in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals.
Gliclazide is an oral anti-diabetic which is recommended for the patients of diabetes mellitus who fail to manage their diabetes by proper diet plan, exercise and insulin therapy. The drug is classified as a sulfonylurea and is marketed as Glyloc and Reclide in India and Diamicron in Canada.
Gliclazide is used for managing hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis prone, maturity-onset or adult type.
Diabetes Mellitus is a group of metabolic diseases linked with high blood sugar with lack of insulin or when cells of the body stop producing insulin. Experts believe that the new treatment will be an effective measure to control and manage diabetes.
Diabetes is one of the widespread long-term disorders in the world. According to the World Health Organization (WHO), there are 220 million people living with diabetes across the world. The main factors responsible for diabetes include urbanization rates, obesity and unhealthy lifestyle.
SUBMITTED BY PRATIBHA MINHAS ON MON, 05/16/2011 - 09:54
China’s SFDA has approved new anti-diabetic drug Gliclazide tablets and it will be sold in the market from July this year. The drug is manufactured by Tianyin Pharmaceutical Co. Inc. the company is specialized in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals.
Gliclazide is an oral anti-diabetic which is recommended for the patients of diabetes mellitus who fail to manage their diabetes by proper diet plan, exercise and insulin therapy. The drug is classified as a sulfonylurea and is marketed as Glyloc and Reclide in India and Diamicron in Canada.
Gliclazide is used for managing hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis prone, maturity-onset or adult type.
Diabetes Mellitus is a group of metabolic diseases linked with high blood sugar with lack of insulin or when cells of the body stop producing insulin. Experts believe that the new treatment will be an effective measure to control and manage diabetes.
Diabetes is one of the widespread long-term disorders in the world. According to the World Health Organization (WHO), there are 220 million people living with diabetes across the world. The main factors responsible for diabetes include urbanization rates, obesity and unhealthy lifestyle.
No comments:
Post a Comment